Patents by Inventor Ian Roger Marsh
Ian Roger Marsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9067899Abstract: Sodium sulfide hydrate is at least partially dehydrated by heating with N-methyl 2-pyrrolidone. 2-Chlorobenzamide is added to the mixture which is heated further. The mixture is cooled and treated with aqueous hydrogen peroxide to give the sodium salt of 1,2-benzisothiazolin-3-one in good yield. Acidification if desired gives rise to the free 1,2-benzisothiazolin-3-one.Type: GrantFiled: April 23, 2013Date of Patent: June 30, 2015Assignee: TITAN CHEMICALS LIMITEDInventors: Carsten Berg, Sangita Singh, Ian Roger Marsh
-
Patent number: 8884024Abstract: N-alkylated 1,2-benzisothiazolin-3-ones can be prepared in good yield and good selectivity by reaction of the lithium salt of 1,2-benzisothiazolin-3-one with an electrophilic alkylating agent.Type: GrantFiled: September 25, 2013Date of Patent: November 11, 2014Assignee: Titan Chemicals LimitedInventor: Ian Roger Marsh
-
Publication number: 20140316141Abstract: Sodium sulfide hydrate is at least partially dehydrated by heating with N-methyl 2-pyrrolidone. 2-Chlorobenzamide is added to the mixture which is heated further. The mixture is cooled and treated with aqueous hydrogen peroxide to give the sodium salt of 1,2-benzisothiazolin-3-one in good yield. Acidification if desired gives rise to the free 1,2-benzisothiazolin-3-one.Type: ApplicationFiled: April 23, 2013Publication date: October 23, 2014Inventors: Carsten BERG, Sangita SINGH, Ian Roger MARSH
-
Patent number: 8685977Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: GrantFiled: July 11, 2011Date of Patent: April 1, 2014Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Marcel John De Groot
-
Patent number: 8592629Abstract: This invention relates to sulfonamide derivative of formula (I), to their use in medicine, to compositions containing them, to processes for their preparation, and to intermediates used in such processes. These compounds are inhibitors of Nav1.7.Type: GrantFiled: July 11, 2011Date of Patent: November 26, 2013Assignee: Pfizer LimitedInventors: Andrew Simon Bell, Alan Daniel Brown, Marcel John De Groot, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Nigel Alan Swain, Steven Matthieu Gaulier
-
Patent number: 8097621Abstract: This invention relates to compounds of formula (I)Type: GrantFiled: June 10, 2009Date of Patent: January 17, 2012Assignee: Pfizer Inc.Inventors: Andrew Simon Bell, David Graham Brown, Kevin Dack, David Nathan Abraham Fox, Ian Roger Marsh, Andrew Ian Morrell, Michael John Palmer, Carol Ann Winslow
-
Publication number: 20120010183Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Het1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Applicant: PFIZER LIMITEDInventors: Andrew Simon Bell, Alan Daniel Brown, Marcel John De Groot, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Nigel Alan Swain, Steven Matthieu Gaulier
-
Publication number: 20120010207Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Applicant: PFIZER LIMITEDInventors: Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Ian Roger Marsh, David Simon Millan, Manuel Perez Pacheco, David James Rawson, Nunzio Sciammetta, Robert Ian Storer, Paul Anthony Stupple, Nigel Alan Swain, Marcel John De Groot
-
Publication number: 20090247539Abstract: This invention relates to compounds of formula (I)Type: ApplicationFiled: June 10, 2009Publication date: October 1, 2009Inventors: Andrew Simon Bell, David Graham Brown, Kevin Dack, David Nathan Abraham Fox, Ian Roger Marsh, Andrew Ian Morrell, Michael John Palmer, Carol Ann Winslow
-
Patent number: 7572799Abstract: This invention relates to compounds of formula (I)Type: GrantFiled: November 24, 2004Date of Patent: August 11, 2009Assignee: Pfizer IncInventors: Andrew Simon Bell, David Graham Brown, Kevin Dack, David Nathan Abraham Fox, Ian Roger Marsh, Andrew Ian Morrell, Michael John Palmer, Carol Ann Winslow
-
Patent number: 7569572Abstract: This invention relates to compounds of formula (I).Type: GrantFiled: March 30, 2005Date of Patent: August 4, 2009Assignee: Pfizer IncInventors: Andrew Simon Bell, David Graham Brown, David Nathan Abraham Fox, Ian Roger Marsh, Andrew Ian Morrell, Dafydd Rhys Owen, Michael John Palmer, Carol Ann Winslow, Hwang Fun Lu, Thomas Edward Rogers
-
Publication number: 20090099209Abstract: Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents H, C1-6alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R2 represents H, C1-6alkyl (optionally substituted by R3), phenyl (optionally substituted by CN), or Het; R3 represents OH, CN, Het, —R4—C1-6alkyl, or CONR5R6; R4 represents —CO2—, or —O—; R5 and R6 independently represent H, C1-6alkyl (optionally substituted by OR7) or C3-8cycloalkyl; R7 represents H or C1-6alkyl; Het represents a five or six membered aromatic heterocyclic group containing (i) from one to four nitrogen heteroatom(s) or (ii) one or two nitrogen heteroatom(s) and one oxygen or one sulphur heteroatom or (iii) one or two oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by one or more groups selected from CN and C1-6alkyl; R8 represents C1-6alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; and R9 and R10 independently represent H, C1-6alkyl, C1-6alkyloxy, CN, CF3 or halo; may be useful for treatiType: ApplicationFiled: December 12, 2008Publication date: April 16, 2009Inventors: Paul Anthony Bradley, Kevin Neil Dack, Ian Roger Marsh
-
Patent number: 7482375Abstract: Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents H, C1-6-alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R2 represents H, C1-6alkyl (optionally substituted by R3), phenyl (optionally substituted by CN), or Het; R3 represents OH, CN, Het, —R4—C1-6alkyl, or CONR5R6; R4 represents —CO2—, or —O—; R5 and R6 independently represent H, C1-6alkyl (optionally substituted by OR7) or C3-8cycloalkyl; R7 represents H or C1-6alkyl; Het represents a five or six membered aromatic heterocyclic group containing (i) from one to four nitrogen heteroatom(s) or (ii) one or two nitrogen heteroatom(s) and one oxygen or one sulphur heteroatom or (iii)one or two oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by one or more groups selected from CN and C1-6alkyl; R8 represents C1-6alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R9 and R10 independently represent H, C1-6alkyl, C1-6alkyloxy, CN, CF3 or halo; may be useful for treating eType: GrantFiled: April 18, 2006Date of Patent: January 27, 2009Assignee: Pfizer Inc.Inventors: Paul Anthony Bradley, Kevin Neil Dack, Ian Roger Marsh
-
Publication number: 20080293697Abstract: This invention relates to compounds of formula (I).Type: ApplicationFiled: March 30, 2005Publication date: November 27, 2008Inventors: Andrew Simon Bell, David Graham Brown, David Nathan Abraham Fox, Ian Roger Marsh, Andrew Ian Morrell, Dafydd Rhys Owen, Michael John Palmer, Carol Ann Winslow, Hwang Fun Lu, Thomas Edward Rogers
-
Patent number: 7262192Abstract: The present invention comprises a class of 5,7-diaminopyrazolo[4,3-d]pyrimidine compounds. These compounds are useful as phosphodiesterase type 5 inhibitors. The present invention further comprises compositions containing the compounds use of the compounds and compositions to treat hypertension and other conditions, processes for the preparation of the compounds, and intermediates used in the preparation of the compounds.Type: GrantFiled: April 29, 2004Date of Patent: August 28, 2007Assignee: Pfizer Inc.Inventors: Andrew Simon Bell, David Graham Brown, David Nathan Abraham Fox, Ian Roger Marsh, Andrew Ian Morrell, Michael John Palmer, Carol Ann Winslow